Recent topics related to etiology and clinical manifestations of cutaneous arteritis

被引:1
|
作者
Ikeda, Takaharu [1 ]
机构
[1] Tohoku Med & Pharmaceut Univ, Fac Med, Div Dermatol, Sendai, Japan
关键词
anti-lysosomal-associated membrane protein-2 antibody; anti-phosphatidylserine-prothrombin complex antibody; cutaneous arteritis; deficiency of adenosine deaminase 2; livedo racemosa; polyarteritis nodosa; ADENOSINE-DEAMINASE; 2; PROTHROMBIN COMPLEX ANTIBODIES; POLYARTERITIS-NODOSA; PERIARTERITIS-NODOSA; DEFICIENCY; MONOCYTES;
D O I
10.3389/fmed.2022.1022512
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cutaneous polyarteritis nodosa (cPAN) was first reported by Lindberg in 1931. It has been recognized as a skin-limited vasculitis whose cutaneous histopathological features are indistinguishable from those of PAN. Cutaneous arteritis (CA) was defined as a form of single-organ vasculitis in the revised Chapel Hill Classification and was recognized as the same disease as cPAN. It became known that deficiency of adenosine deaminase 2 (DADA2) cases were included in cases that had been diagnosed with CA. Because of their similarity and differences in the treatment methods, DADA2 should be considered in CA cases, especially if they are diagnosed or developed in early childhood. Cutaneous arteritis may be classified as an immune complex-mediated vasculitis. It was reported that the pathogenesis of anti-lysosomal-associated membrane protein-2 (LAMP-2) antibodies and anti-phosphatidylserine-prothrombin complex (PS/PT) antibodies as good parameters in CA. The main skin manifestations include livedo racemosa, subcutaneous nodules, and ulcers. Although CA is recognized to have a benign clinical course, it has become known that it is easy to relapse. The existence of skin ulcers upon diagnosis or sensory neuropathies was suggested to be a predictor of poor prognosis. Cutaneous arteritis with them may need to be treated with more intensive therapies.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Clinical manifestations of cutaneous lupus erythematosus
    Werth, VP
    AUTOIMMUNITY REVIEWS, 2005, 4 (05) : 296 - 302
  • [32] ETIOLOGY, CLINICAL MANIFESTATIONS AND PROGNOSIS OF THE RADIATION NEPHRITIS
    BOTTCHER, HD
    SCHNEPPER, E
    STRAHLENTHERAPIE, 1983, 159 (03) : 168 - 172
  • [33] ROOT RESORPTION - ETIOLOGY, TERMINOLOGY AND CLINICAL MANIFESTATIONS
    TRONSTAD, L
    ENDODONTICS & DENTAL TRAUMATOLOGY, 1988, 4 (06): : 241 - 252
  • [34] PNEUMONIA IN PEDIATRIC OUTPATIENTS - ETIOLOGY AND CLINICAL MANIFESTATIONS
    TURNER, RB
    LANDE, A
    CHASE, P
    HILTON, N
    WEINBERG, D
    CLINICAL RESEARCH, 1987, 35 (01): : A145 - A145
  • [35] Clinical manifestations of temporal arteritis: A report from Israel
    Gur, H
    Rapman, E
    Ehrenfeld, M
    Sidi, Y
    JOURNAL OF RHEUMATOLOGY, 1996, 23 (11) : 1927 - 1931
  • [36] CLINICAL MANIFESTATIONS OF OCCULT GIANT-CELL ARTERITIS
    HADDAD, R
    WINKLER, E
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 1983, 183 (05) : 389 - 390
  • [37] Wegener's granulomatosis with clinical manifestations of temporal arteritis
    Astudillo, L.
    Pugnet, G.
    Bidegain, F.
    Delsol, A.
    Fortenfant, F.
    Arlet-Suau, E.
    REVUE DE MEDECINE INTERNE, 2008, 29 (10): : 830 - 831
  • [38] CLINICAL AND IMAGING FEATURES FOR CEREBROVASCULAR MANIFESTATIONS IN TAKAYASU ARTERITIS
    Lee, K.
    Kwon, S. U.
    Lee, M.
    INTERNATIONAL JOURNAL OF STROKE, 2018, 13 : 135 - 135
  • [39] CLINICAL MANIFESTATIONS OF GIANT-CELL (TEMPORAL) ARTERITIS
    CALAMIA, KT
    HUNDER, GG
    CLINICS IN RHEUMATIC DISEASES, 1980, 6 (02): : 389 - 403
  • [40] GIANT-CELL ARTERITIS - A SYSTEMIC-DISEASE WITH RARE CUTANEOUS MANIFESTATIONS
    BAUM, EW
    SAMS, WM
    PAYNE, RR
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1982, 6 (06) : 1081 - 1088